Earnings Feed
Start Free
Home/Filings/4/0001209191-18-055186
4//SEC Filing

Tabibiazar Raymond 4

Accession 0001209191-18-055186

CIK 0001513818other
View on SEC.govCompany Profile

Filed

Oct 15, 8:00 PM ET

Accepted

Oct 16, 6:21 PM ET

Size

43.8 KB

Accession

0001209191-18-055186

Insider Transaction Report

Form 4
Period: 2018-10-12
Aravive, Inc.ARAV
Tabibiazar Raymond
Director10% Owner
Transactions
  • Award

    Stock Option (Right to Buy)

    2018-10-12+46,322→ 46,322 total
    Exercise: $0.06Exp: 2021-04-25→ Common Stock (46,322 underlying)
  • Award

    Stock Option (Right to Buy)

    2018-10-12+12,084→ 12,084 total
    Exercise: $0.06Exp: 2021-04-25→ Common Stock (12,084 underlying)
  • Award

    Stock Option (Right to Buy)

    2018-10-12+15,200→ 15,200 total
    Exercise: $0.24Exp: 2024-12-31→ Common Stock (15,200 underlying)
  • Award

    Stock Option (Right to Buy)

    2018-10-12+254,177→ 254,177 total
    Exercise: $0.24Exp: 2025-06-30→ Common Stock (254,177 underlying)
  • Award

    Common Stock

    2018-10-12+1,000,751→ 1,000,751 total
  • Award

    Stock Option (Right to Buy)

    2018-10-12+51,682→ 51,682 total
    Exercise: $0.24Exp: 2024-09-30→ Common Stock (51,682 underlying)
  • Award

    Stock Option (Right to Buy)

    2018-10-12+15,200→ 15,200 total
    Exercise: $0.24Exp: 2025-03-31→ Common Stock (15,200 underlying)
  • Award

    Stock Option (Right to Buy)

    2018-10-12+15,200→ 15,200 total
    Exercise: $0.24Exp: 2026-03-31→ Common Stock (15,200 underlying)
  • Award

    Stock Option (Right to Buy)

    2018-10-12+28,501→ 28,501 total
    Exercise: $0.90Exp: 2027-12-14→ Common Stock (28,501 underlying)
  • Award

    Stock Option (Right to Buy)

    2018-10-12+15,200→ 15,200 total
    Exercise: $0.24Exp: 2025-06-30→ Common Stock (15,200 underlying)
  • Award

    Stock Option (Right to Buy)

    2018-10-12+15,200→ 15,200 total
    Exercise: $0.24Exp: 2025-09-30→ Common Stock (15,200 underlying)
  • Award

    Stock Option (Right to Buy)

    2018-10-12+57,002→ 57,002 total
    Exercise: $0.66Exp: 2027-06-15→ Common Stock (57,002 underlying)
  • Award

    Stock Option (Right to Buy)

    2018-10-12+65,365→ 65,365 total
    Exercise: $0.24Exp: 2025-06-30→ Common Stock (65,365 underlying)
  • Award

    Stock Option (Right to Buy)

    2018-10-12+15,200→ 15,200 total
    Exercise: $0.24Exp: 2025-12-31→ Common Stock (15,200 underlying)
  • Award

    Stock Option (Right to Buy)

    2018-10-12+28,501→ 28,501 total
    Exercise: $0.90Exp: 2028-03-20→ Common Stock (28,501 underlying)
Footnotes (15)
  • [F1]Shares of common stock of the corporation known as Aravive Biologics, Inc. ("Aravive") were converted into shares of the issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of June 3, 2018, by and among the Issuer, Velo Merger Sub, Inc. and Aravive (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of Aravive common stock was exchanged for 2.2801 shares of the Issuer's common stock, subject to adjustment for any reverse stock split. Following the merger, the Issuer effected a reverse stock split at a ratio of one new share for every six shares of Issuer common stock outstanding and the Issuer changed its name to Aravive, Inc. All share and option numbers reflect the reverse stock split.
  • [F10]On September 30, 2015, Reporting Person was granted an option to purchase 40,000 shares of the common stock of Aravive at an exercise price of $0.09 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 15,200 shares of Issuer common stock (as adjusted for the stock split) at a per share exercise price of $0.24 per share (as adjusted for the stock split). The option is fully vested with respect to all of the underlying shares and exercisable as of the effective date of the merger.
  • [F11]On December 31, 2015, Reporting Person was granted an option to purchase 40,000 shares of the common stock of Aravive at an exercise price of $0.09 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 15,200 shares of Issuer common stock (as adjusted for the stock split) at a per share exercise price of $0.24 per share (as adjusted for the stock split). The option is fully vested with respect to all of the underlying shares and exercisable as of the effective date of the merger.
  • [F12]On March 31, 2016, Reporting Person was granted an option to purchase 40,000 shares of the common stock of Aravive at an exercise price of $0.09 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 15,200 shares of Issuer common stock (as adjusted for the stock split) at a per share exercise price of $0.24 per share (as adjusted for the stock split). The option is fully vested with respect to all of the underlying shares and exercisable as of the effective date of the merger.
  • [F13]On June 15, 2017, Reporting Person was granted an option to purchase 150,000 shares of the common stock of Aravive at an exercise price of $0.23 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 57,002 shares of Issuer common stock (as adjusted for the stock split) at a per share exercise price of $0.66 per share (as adjusted for the stock split). The option is fully vested with respect to all of the underlying shares and exercisable as of the effective date of the merger.
  • [F14]On December 14, 2017, Reporting Person was granted an option to purchase 75,000 shares of the common stock of Aravive at an exercise price of $0.34 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 28,501 shares of Issuer common stock (as adjusted for the stock split) at a per share exercise price of $0.90 per share (as adjusted for the stock split). The option is fully vested with respect to all of the underlying shares and exercisable as of the effective date of the merger.
  • [F15]On March 20, 2018, Reporting Person was granted an option to purchase 75,000 shares of the common stock of Aravive at an exercise price of $0.34 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 28,501 shares of Issuer common stock (as adjusted for the stock split) at a per share exercise price of $0.90 per share (as adjusted for the stock split). The option is fully vested with respect to all of the underlying shares and exercisable as of the effective date of the merger.
  • [F2]On April 26, 2011, Reporting Person was granted an option to purchase 121,897 shares of the common stock of Aravive at an exercise price of $0.02 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 46,332 shares of Issuer common stock (as adjusted for the stock split) at a per share exercise price of $0.06 per share (as adjusted for the stock split). The option is fully vested with respect to all of the underlying shares and exercisable as of the effective date of the merger.
  • [F3]On April 26, 2011, Reporting Person was granted an option to purchase 31,799 shares of the common stock of Aravive at an exercise price of $0.02 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 12,084 shares of Issuer common stock (as adjusted for the stock split) at a per share exercise price of $0.06 per share (as adjusted for the stock split). The option is fully vested with respect to all of the underlying shares and exercisable as of the effective date of the merger.
  • [F4]On October 1, 2014, Reporting Person was granted an option to purchase 136,000 shares of the common stock of Aravive at an exercise price of $0.09 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 51,682 shares of Issuer common stock (as adjusted for the stock split) at a per share exercise price of $0.24 per share (as adjusted for the stock split). The option is fully vested with respect to all of the underlying shares and exercisable as of the effective date of the merger.
  • [F5]On December 31, 2014, Reporting Person was granted an option to purchase 40,000 shares of the common stock of Aravive at an exercise price of $0.09 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 15,200 shares of Issuer common stock (as adjusted for the stock split) at a per share exercise price of $0.24 per share (as adjusted for the stock split). The option is fully vested with respect to all of the underlying shares and exercisable as of the effective date of the merger.
  • [F6]On March 31, 2015, Reporting Person was granted an option to purchase 40,000 shares of the common stock of Aravive at an exercise price of $0.09 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 15,200 shares of Issuer common stock (as adjusted for the stock split) at a per share exercise price of $0.24 per share (as adjusted for the stock split). The option is fully vested with respect to all of the underlying shares and exercisable as of the effective date of the merger.
  • [F7]On June 30, 2015, Reporting Person was granted an option to purchase 40,000 shares of the common stock of Aravive at an exercise price of $0.09 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 15,200 shares of Issuer common stock (as adjusted for the stock split) at a per share exercise price of $0.24 per share (as adjusted for the stock split). The option is fully vested with respect to all of the underlying shares and exercisable as of the effective date of the merger.
  • [F8]On July 1, 2015, Reporting Person was granted an option to purchase 172,006 shares of the common stock of Aravive at an exercise price of $0.09 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 65,365 shares of Issuer common stock (as adjusted for the stock split) at a per share exercise price of $0.24 per share (as adjusted for the stock split). The option is fully vested with respect to all of the underlying shares and exercisable as of the effective date of the merger.
  • [F9]On July 29, 2015, Reporting Person was granted an option to purchase 668,858 shares of the common stock of Aravive at an exercise price of $0.09 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 254,177 shares of Issuer common stock (as adjusted for the stock split) at a per share exercise price of $0.24 per share (as adjusted for the stock split). The option is fully vested with respect to all of the underlying shares and exercisable as of the effective date of the merger.

Documents

1 file

Issuer

Aravive, Inc.

CIK 0001513818

→
Entity typeother

Related Parties

1
  • filerCIK 0001753279

Filing Metadata

Form type
4
Filed
Oct 15, 8:00 PM ET
Accepted
Oct 16, 6:21 PM ET
Size
43.8 KB
View on SEC.gov